Denning v. Bond Pharmacy

50 F.4th 445
CourtCourt of Appeals for the Fifth Circuit
DecidedSeptember 30, 2022
Docket21-30534
StatusPublished
Cited by25 cases

This text of 50 F.4th 445 (Denning v. Bond Pharmacy) is published on Counsel Stack Legal Research, covering Court of Appeals for the Fifth Circuit primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Denning v. Bond Pharmacy, 50 F.4th 445 (5th Cir. 2022).

Opinion

Case: 21-30534 Document: 00516491629 Page: 1 Date Filed: 09/30/2022

United States Court of Appeals for the Fifth Circuit United States Court of Appeals Fifth Circuit

FILED September 30, 2022 No. 21-30534 Lyle W. Cayce Clerk

Randy Denning,

Plaintiff—Appellant,

versus

Bond Pharmacy, Incorporated, doing business as Advanced Infusion Care, doing business as Advanced Infusion Solutions, doing business as AIS Healthcare,

Defendant—Appellee.

Appeal from the United States District Court for the Eastern District of Louisiana USDC No. 2:21-CV-774

Before Stewart, Clement, and Elrod, Circuit Judges. Carl E. Stewart, Circuit Judge: In 2019, Randy Denning began receiving prescription medication administered through a pain pump and filled by AIS Healthcare (“AIS”). In 2021, she discovered that AIS was billing her insurer at a rate of $120 per day for allegedly unauthorized services. Denning filed suit in state court, seeking damages for contract, tort, and unjust enrichment claims. AIS removed to federal court and moved to dismiss the case on grounds that Denning lacked standing to sue because she had suffered no injury. Noting that “a breach of Case: 21-30534 Document: 00516491629 Page: 2 Date Filed: 09/30/2022

No. 21-30534

contract alone is an insufficient injury in fact,” the district court concluded that Denning could not satisfy standing’s redressability element for the claims asserted and dismissed them with prejudice under Rule 12(b)(1). See FED. R. CIV. P. 12(b)(1). For the following reasons, we affirm the district court’s judgment dismissing Denning’s claims for lack of standing, however, we modify the judgment to make it without prejudice and affirm as modified. I. FACTUAL & PROCEDURAL BACKGROUND In October 2019, Denning began receiving outpatient care for chronic pain with medication administered through an intrathecal pain pump. This pump is implanted under the skin and filled with a customized medication that it delivers through a catheter directly to the spinal cord. It can deliver medication at scheduled intervals for several months before requiring a refill, enabling a patient to receive day-to-day pain treatment outside of an in- patient healthcare facility. According to Denning, her physician prescribed medication to be filled by AIS which is a national compounding pharmacy that provides specialized home infusion therapy using pain pumps. Denning signed two agreements with AIS in October 2019. The first authorized AIS to provide services to Denning pursuant to the orders of her physician. The second assigned to AIS insurance benefits payable for products or services provided by the pharmacy. In February 2021, Denning discovered that AIS had billed her insurer at a daily rate of $120 for services that she alleges neither she nor her physician had authorized. The following month, Denning filed a petition in Louisiana state court seeking compensatory and punitive damages, and alternatively, restitution. Denning’s petition included state law claims for

2 Case: 21-30534 Document: 00516491629 Page: 3 Date Filed: 09/30/2022

breach of contract, unjust enrichment, and fraudulent misrepresentation. 1 She asserted her claims individually and on behalf of a class of hundreds of similarly situated Louisiana patients billed by AIS over the last decade. AIS removed the suit to federal district court and filed a motion to dismiss the petition or strike the class action allegations. In doing so, AIS argued that (1) the case should be dismissed under Rule 12(b)(1) for lack of standing; (2) the claims for unjust enrichment and fraudulent misrepresentation should otherwise be dismissed under 12(b)(6) for failure to state a claim; and (3) if claims remain, Denning’s class action allegations should be stricken for failure to show a predominance of common issues among a proposed class. See FED. R. CIV. P. 12(b)(1), (6). According to AIS, Denning lacked standing to assert her claims because she suffered no injury. AIS reasoned that Denning had not alleged that she paid any of the billed amounts or that AIS had threatened collection proceedings against her. Rather, she had alleged only that her insurer wrongfully paid for billed services. Thus, AIS argued, Denning had suffered no financial loss and allegedly could not show an injury for standing purposes. 2 In her opposition to AIS’s motion, Denning conceded that she suffered no financial loss but averred that the alleged billing practices nevertheless resulted in a redressable injury. According to Denning, “[a] party to a contract undoubtedly has standing to file a suit for breach of that

1 In Denning’s opening brief, she refers to both “intentional misrepresentation” and “negligent misrepresentation.” Because Denning did not raise negligent misrepresentation in her petition, however, it is “not properly before the court” and we decline to address it. Fisher v. Metro. Life Ins. Co., 895 F.2d 1073, 1078 (5th Cir. 1990). 2 Although AIS did not file an answer before Denning’s claims were dismissed, it stated in its motion and in oral argument before this court that it disputes her allegation that the charges were unauthorized.

3 Case: 21-30534 Document: 00516491629 Page: 4 Date Filed: 09/30/2022

contract,” and several violations of Louisiana law arising from AIS’s billing activities could serve as a basis for standing. In August 2021, the district court granted AIS’s Rule 12(b)(1) motion to dismiss on grounds that Denning had failed to establish standing for her claims. In its reasons, the district court observed that “[c]ourts in other circuits are wrestling with the question of whether a breach of contract alone, without any further harm or injury, constitutes an injury in fact for standing purposes.” After noting that the Fifth Circuit has not directly addressed this question, the district court concluded that “[i]t appears . . . Article III standing requires a concrete injury to plaintiff such that a breach of contract alone is an insufficient injury in fact.” In support, the district court cited the Supreme Court’s reasoning in Spokeo, Inc. v. Robins that standing requires a concrete injury, “even in the context of a statutory violation.” 578 U.S. 330, 341 (2016). However, the district court did not rest its disposition on an injury in fact analysis and ultimately held that Denning could not satisfy standing’s redressability element. The district court reasoned that “if Plaintiff has not suffered any concrete losses . . . there is nothing to compensate.” It explained that the disgorgement of funds paid by Denning’s insurer would only redress the insurer’s injury, not hers. The district court then dismissed Denning’s claims with prejudice. This appeal followed. II. STANDARD OF REVIEW “Standing is a question of law that we review de novo.” Rivera v. Wyeth-Ayerst Lab’ys, 283 F.3d 315, 319 (5th Cir. 2002). “We review for clear error all facts expressly or impliedly found by the district court.” Id. “[W]hen ruling on a defendant’s motion to dismiss, a judge must accept as true all of the factual allegations contained in the complaint.” Erickson v. Pardus, 551 U.S. 89, 94 (2007) (citing Bell Atl. Corp. v. Twombly, 550 U.S. 544, 555– 56 (2007)). “Since they are not mere pleading requirements, but rather an indispensable part of the plaintiff[’]s case, each element of standing must be

4 Case: 21-30534 Document: 00516491629 Page: 5 Date Filed: 09/30/2022

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Cite This Page — Counsel Stack

Bluebook (online)
50 F.4th 445, Counsel Stack Legal Research, https://law.counselstack.com/opinion/denning-v-bond-pharmacy-ca5-2022.